A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE

Figure 3

Construction of the prognostic signature. (a) A coefficient profile plot was generated against the log () sequence. (b) LASSO coefficient profiles of the eight genes associated with poor prognosis of patients treated with TACE. The coefficient of three genes was not 0 in GSE14520. (c) Risk scores of patients treated with TACE in GSE14520 and median risk score. (d) The K–M curve shows that OS was lower in the high-risk than in the low-risk group in patients treated with TACE in GSE14520. (e) The area-under-the-curve (AUC) value of the time-dependent receiver operating characteristic (ROC) curve shows the prognostic performance of the signature in GSE14520. (f) Difference in risk score between TACE response and nonresponse groups in GSE104580.

(a)

(b)

(c)

(d)

(e)

(f)